Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $105.00 short put and a strike $97.50 long put offers a potential 7.45% return on risk over the next 31 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $0.52 would be kept by the premium seller. The risk of $6.98 would be incurred if the stock dropped below the $97.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 62.82 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Top Stocks: IBD Screens Uncover Emerging Leaders Before Big Moves
Fri, 16 Nov 2018 18:45:43 +0000
It's been frustrating market for growth investors, but the savviest ones continue to build their watch lists with top stocks acting well.
Gauging Analysts’ Views on Clovis Stock
Fri, 16 Nov 2018 14:00:57 +0000
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
Eli Lilly considers sale of off-patent drug assets in China – Bloomberg
Fri, 16 Nov 2018 13:56:55 +0000
Eli Lilly and Co is considering the sale of an off-patent drugs portfolio in China, Bloomberg reported on Friday, citing sources. The assets, which include antibiotics and treatments for central nerve …
Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings
Fri, 16 Nov 2018 13:35:01 +0000
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
Fri, 16 Nov 2018 12:59:12 +0000
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Also on Market Tamer…
Follow Us on Facebook